NasdaqGM - Nasdaq Real Time Price USD
Keros Therapeutics, Inc. (KROS)
14.45
+0.19
+(1.33%)
At close: April 29 at 4:00:01 PM EDT
14.40
-0.05
(-0.35%)
After hours: April 29 at 7:35:23 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 237,367 | 5 |
| Sales | 40,000 | 1 |
| Net Shares Purchased (Sold) | 197,367 | 6 |
| Total Insider Shares Held | 980.79k | -- |
| % Net Shares Purchased (Sold) | 25.20% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| SEEHRA JASBIR Chief Executive Officer | Conversion of Exercise of derivative security at price 0.30 per share. | Direct | 14,810 | Apr 4, 2025 |
| REGNANTE KEITH C Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 18, 2025 |
| ROVALDI CHRISTOPHER Chief Operating Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 18, 2025 |
| CHYUNG YUNG H. M.D. Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 18, 2025 |
| GORDON CARL L Director | Sale at price 44.01 per share. | Indirect | 11,002,500 | Aug 13, 2024 |
| ORBIMED ADVISORS, L.L.C. Unknown | Sale at price 44.01 per share. | Indirect | 11,002,500 | Aug 13, 2024 |
| REGNANTE KEITH C Chief Financial Officer | Sale at price 45.29 per share. | Direct | 1,811,600 | Jan 4, 2024 |
| REGNANTE KEITH C Chief Financial Officer | Conversion of Exercise of derivative security at price 16.00 per share. | Direct | 640,000 | Jan 4, 2024 |
| REGNANTE KEITH C Chief Financial Officer | Sale at price 31.94 per share. | Direct | 1,277,600 | Nov 3, 2023 |
| REGNANTE KEITH C Chief Financial Officer | Conversion of Exercise of derivative security at price 16.00 per share. | Direct | 640,000 | Nov 3, 2023 |
| REGNANTE KEITH C Chief Financial Officer | Sale at price 45.03 - 48.65 per share. | Direct | 1,864,239 | Jun 9, 2023 |
| REGNANTE KEITH C Chief Financial Officer | Conversion of Exercise of derivative security at price 16.00 per share. | Direct | 640,000 | Jun 9, 2023 |
Related Tickers
EPIX ESSA Pharma Inc.
1.7700
-1.12%
ASMB Assembly Biosciences, Inc.
11.51
+6.38%
HLVX HilleVax, Inc.
1.9300
+2.66%
IPSC Century Therapeutics, Inc.
0.5041
+1.31%
VTYX Ventyx Biosciences, Inc.
1.2800
+3.23%
SPRO Spero Therapeutics, Inc.
0.6710
-5.49%
RPTX Repare Therapeutics Inc.
1.3200
-2.94%
IKNA Ikena Oncology, Inc.
1.3000
+2.36%
GLTO Galecto, Inc.
2.6800
0.00%
TIL Instil Bio, Inc.
11.72
-5.79%